{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:25:43Z","timestamp":1787009143782,"version":"build-2736575974"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA"},{"name":"US National Cancer Institute Center for Cancer Research, National Cancer Research, Bethesda"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Randomized controlled trials are the gold standard for demonstrating treatment efficacy. When infeasible, external control arm (ECA) analysis is an effective way to interpret treatment arm results. We developed an ECA for a single-arm trial (LS-004) for a HIF-2\u03b1 inhibitor (belzutifan) in 61 patients with VHL renal cell carcinoma (RCC) to help interpret results. With a median follow-up of 37.8\u2009months in LS-004, the ORR was 64% (95% CI = 50.6 to 75.8); median time to surgery was not reached.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The ECA was developed using natural history study data for VHL RCC patients undergoing active surveillance with \u22645\u2009years of follow-up. Key LS-004 eligibility criteria were applied. Propensity score (PS) weighting was used to balance prognostic factors, with balance evaluated using standardized mean difference (SMD). PS adjusted point estimates and 95% CI for ORR and time to surgery (TTS) are presented. For the ECA, ORR was evaluated among patients with \u22653 scans to allow opportunity for a confirmed response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The ECA included 244 patients (167 for ORR analysis). Prognostic factors were balanced with SMD\u2009&amp;lt;\u20090.1 for all covariates. PS adjusted ORR for LS-004 and ECA was 63.9% (95% CI = 51.9 to 76.0) and 1.5% (95% CI = 0.0 to 3.3), respectively. Median TTS was 51.3 (95% CI = 43.8 to not yet reached) months in ECA; not yet reached in LS-004.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The belzutifan treatment effect is large compared with the ECA, supporting belzutifan efficacy in VHL RCC. Although residual confounding is possible, the large effect is unlikely due to chance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jnci\/djag064","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T12:22:05Z","timestamp":1774268525000},"page":"1081-1088","source":"Crossref","is-referenced-by-count":2,"title":["Belzutifan efficacy in von Hippel-Lindau disease-associated renal cell carcinoma versus natural history control arm"],"prefix":"10.1093","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7983-3109","authenticated-orcid":false,"given":"W Marston","family":"Linehan","sequence":"first","affiliation":[{"name":"Urologic Oncology Branch, National Cancer Institute , Bethesda, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7788-1828","authenticated-orcid":false,"given":"Thomas","family":"Jemielita","sequence":"additional","affiliation":[{"name":"Biostatistics and Research Decision Sciences, Merck & Co., Inc , Rahway, NJ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Cornell","sequence":"additional","affiliation":[{"name":"Biostatistics and Research Decision Sciences, Merck & Co., Inc , Rahway, NJ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Chen","sequence":"additional","affiliation":[{"name":"Biostatistics and Research Decision Sciences, Merck & Co., Inc , Rahway, NJ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1780-2627","authenticated-orcid":false,"given":"Mark W","family":"Ball","sequence":"additional","affiliation":[{"name":"Urologic Oncology Branch, National Cancer Institute , Bethesda, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramaprasad","family":"Srinivasan","sequence":"additional","affiliation":[{"name":"Urologic Oncology Branch, National Cancer Institute , Bethesda, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Liu","sequence":"additional","affiliation":[{"name":"Clinical Research, Merck & Co., Inc , Rahway, NJ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4400-5260","authenticated-orcid":false,"given":"Rodolfo F","family":"Perini","sequence":"additional","affiliation":[{"name":"Clinical Research, Merck & Co., Inc , Rahway, NJ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7793-1706","authenticated-orcid":false,"given":"Cathy Anne","family":"Pinto","sequence":"additional","affiliation":[{"name":"Biostatistics and Research Decision Sciences, Merck & Co., Inc , Rahway, NJ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"2026060908532781300_djag064-B1","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von Hippel-Lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N Engl J Med"},{"key":"2026060908532781300_djag064-B2"},{"key":"2026060908532781300_djag064-B3","doi-asserted-by":"publisher","first-page":"e024895","DOI":"10.1136\/bmjopen-2018-024895","article-title":"Characteristics of non-randomised studies using comparisons with external controls submitted for regulatory approval in the USA and Europe: a systematic review","volume":"9","author":"Goring","year":"2019","journal-title":"BMJ Open"},{"key":"2026060908532781300_djag064-B4","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s43441-021-00302-y","article-title":"The use of external controls in FDA regulatory decision making","volume":"55","author":"Jahanshahi","year":"2021","journal-title":"Ther Innov Regul Sci"},{"key":"2026060908532781300_djag064-B5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.eururo.2025.03.002","article-title":"Longitudinal evaluation of clear-cell renal cell carcinoma in von Hippel-Lindau disease","volume":"88","author":"Linehan","year":"2025","journal-title":"Eur Urol"},{"key":"2026060908532781300_djag064-B6","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.annonc.2021.12.015","article-title":"External control arms in oncology: current use and future directions","volume":"33","author":"Mishra-Kalyani","year":"2022","journal-title":"Ann Oncol"},{"key":"2026060908532781300_djag064-B7","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.euo.2023.01.012","article-title":"A matching-adjusted indirect comparison of nivolumab plus cabozantinib versus pembrolizumab plus axitinib in patients with advanced renal cell carcinoma","volume":"6","author":"McGregor","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"2026060908532781300_djag064-B8","doi-asserted-by":"publisher","first-page":"e473","DOI":"10.1038\/bcj.2016.84","article-title":"Blinatumomab vs historical standard therapy of adult relapsed\/refractory acute lymphoblastic leukemia","volume":"6","author":"G\u00f6kbuget","year":"2016","journal-title":"Blood Cancer J"},{"key":"2026060908532781300_djag064-B9","author":"NDA Multi-disciplinary Review and Evaluation of BALVERSA (erdafitinib)"},{"key":"2026060908532781300_djag064-B10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2026060908532781300_djag064-B11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3389\/fped.2018.00016","article-title":"Renal cell carcinoma in von Hippel-Lindau disease\u2014from tumor genetics to novel therapeutic strategies","volume":"6","author":"Kim","year":"2018","journal-title":"Front Pediatr"},{"key":"2026060908532781300_djag064-B12"},{"key":"2026060908532781300_djag064-B13","doi-asserted-by":"publisher","first-page":"5642","DOI":"10.1002\/sim.7084","article-title":"Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis","volume":"35","author":"Austin","year":"2016","journal-title":"Stat Med"},{"key":"2026060908532781300_djag064-B14","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1524-4733.2009.00671.x","article-title":"Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals","volume":"13","author":"Xu","year":"2010","journal-title":"Value Health"},{"key":"2026060908532781300_djag064-B15","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/biom.13405","article-title":"Power and sample size for observational studies of point exposure effects","volume":"78","author":"Shook-Sa","year":"2022","journal-title":"Biometrics"},{"key":"2026060908532781300_djag064-B16","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1016\/j.jclinepi.2013.01.013","article-title":"Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research","volume":"66","author":"Stuart","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"2026060908532781300_djag064-B17"},{"key":"2026060908532781300_djag064-B18"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djag064\/67992727\/djag064.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/118\/6\/1081\/67992727\/djag064.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/118\/6\/1081\/67992727\/djag064.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T12:53:32Z","timestamp":1781009612000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/118\/6\/1081\/8644271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":18,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,4,8]]},"published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djag064","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,4,8]]}}}